Tirzepatide
Tirzepatide (Dual GIP/GLP-1 Receptor Agonist)
Dual Agonist Peptide for Weight Loss
What is Tirzepatide?
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Unlike semaglutide which targets only GLP-1 receptors, tirzepatide activates both GIP and GLP-1 receptors, providing a dual mechanism of action for blood sugar control and weight management.
Originally developed for type 2 diabetes and marketed as Mounjaro, tirzepatide has demonstrated remarkable weight loss results in clinical trials. The SURMOUNT trials showed that participants lost up to 22.5% of their body weight over 72 weeks, making it one of the most effective weight loss therapies available.
Tirzepatide works by enhancing insulin secretion in a glucose-dependent manner, suppressing glucagon, slowing gastric emptying, and reducing appetite through central nervous system pathways. The dual-agonist approach provides complementary metabolic benefits beyond what single-receptor agonists can achieve.
Research Supply
Source high-purity Tirzepatide for your research
Dosage Guide
Route: Subcutaneous injection, once weekly
Dosing Schedule
| Period | Dose |
|---|---|
| Weeks 1-4 | 2.5 mg |
| Weeks 5-8 | 5.0 mg |
| Weeks 9-12 | 7.5 mg |
| Weeks 13-16 | 10.0 mg |
| Weeks 17-20 | 12.5 mg |
| Week 21+ | 15.0 mg (maximum maintenance) |
Reconstitution
Injection Volumes
| Dose | Volume | Syringe Units |
|---|---|---|
| 2.5 mg | 0.5 mL | 50 units |
| 5.0 mg | 1.0 mL | 100 units |
| 7.5 mg | 1.5 mL | Use two injections |
| 10.0 mg | 2.0 mL | Use two injections |
Administration Tips
- Inject subcutaneously in the abdomen, thigh, or upper arm
- Rotate injection sites with each injection
- Administer on the same day each week
- Store reconstituted solution refrigerated and use within 28 days
- Use a standard U-100 insulin syringe for accurate measurement
Risks & Side Effects
Commonly Reported
Serious Risks
Pancreatitis
Acute inflammation of the pancreas; seek medical attention for severe, persistent abdominal pain.
Gallbladder disease
Including gallstones and cholecystitis.
Hypoglycemia
Particularly when used with insulin or sulfonylureas.
Kidney injury
Often secondary to dehydration from gastrointestinal effects.
Allergic reactions
Including potential anaphylaxis.
Thyroid C-cell tumors
Boxed warning based on rodent studies; contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Gastroparesis
Severe slowing of gastric emptying in some individuals.
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to tirzepatide
- Pregnancy or breastfeeding
- Severe gastrointestinal disease
Frequently Asked Questions
Related Peptides
Experts Covering Tirzepatide
Dr. William A. Seeds
MD -- Regenerative Medicine Pioneer
Dr. Andrew Huberman
PhD -- Stanford Neuroscientist
Jay Campbell
Health Optimization Author and Peptide Advocate
Dr. Ian W. Hamley
Diamond Professor of Physical Chemistry -- University of Reading
Matthew Farrahi
Biohacker, CEO of Sigma Compounds, and Fitness Creator
LEGAL DISCLAIMER
The information provided on this page is for educational and informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.